{"entity":{"id":"nct03579836","kind":"trial","name":"Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by BeyondBio Inc., now recruiting.","summary":"Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer is a phase 1/2 interventional study registered as NCT03579836 by BeyondBio Inc., with 75 participants planned, started 2018-05-14 and due to reach its primary completion in 2026-11-30. Interventions recorded: BEY1107 and Gemcitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03579836","url":"https://clinicaltrials.gov/study/NCT03579836"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03579836","phase":"1/2","setting":"A Single Center, Open-label, Non-comparative, Phase I/II Clinical Trial to Assess the MTD, Safety and Efficacy of BEY1107 in Monotherapy and in Combination with Gemcitabine in Patient with Locally Advanced or Metastatic Pancreatic Cancer","sponsor":"BeyondBio Inc.","enrolled":75,"outcomes":[]},"route":"/trials/nct03579836/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}]}}